Form 4: United Therapeutics EVP Exercises Options, Sells Shares

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold the resulting shares under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp (UTHR), exercised 8,300 stock options at an exercise price of $146.03 per share.
• Concurrently, Mr. Mahon sold all 8,300 shares acquired from the option exercise in multiple transactions.
• The sales occurred at weighted average prices ranging from $471.3587 to $478.9182 per share.
• These transactions were executed on February 19, 2026, as part of a pre-arranged Rule 10b5-1 trading plan established on August 11, 2025.
• Following these transactions, Mr. Mahon's direct beneficial ownership of common stock is 36,781 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan, which is common for executive compensation and personal financial management.

Positives

• The exercise of stock options indicates that the executive is realizing value from previously granted equity compensation.
• The transactions were conducted under a pre-arranged 10b5-1 plan, which suggests the sales were not based on new, non-public information.

Negatives

• The sale of shares by a senior executive, even if pre-planned, reduces their direct ownership stake in the company.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under a Rule 10b5-1 plan, are common for executives managing their personal finances and diversifying their portfolios. While a sale reduces an executive's direct stake, the pre-planned nature mitigates concerns about it being a reaction to new, negative company-specific information. This is a routine disclosure for executive compensation realization.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are standard practice across industries, including biotechnology and pharmaceuticals, for executives to manage liquidity and diversify holdings. There are no specific comparable companies or projects mentioned in this filing to benchmark against, as this is a personal transaction by an executive.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be perceived as a slight negative, but the pre-planned nature under a 10b5-1 plan generally mitigates concerns about its implications for company performance.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Key Dates

Recommendation

The filing details a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. This type of transaction is common for executive compensation and personal financial management and does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this event does not provide new information to alter an existing investment thesis.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Executive Compensation, Share Sale, 10b5-1 Plan, Paul A. Mahon, Biotechnology, Pharmaceuticals